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a b s t r a c t
Four different market classes of peanut (Runner, Virginia Spanish, and Valencia) are commonly
consumed in Western countries, but for some consumers peanuts are a main cause of food-induced
anaphylaxis. Limited information is available on the comparative allergenicity of these distinct market
classes. The aim of this study was to compare allergenicity attributes of different peanut cultivars.
The protein content and protein profiles were highly comparable for all tested cultivars. All cultivar
samples contained the major allergens Ara h 1, Ara h 2, Ara h 3 and Ara h 6, as assessed by SDS-PAGE and
RP-HPLC, although some minor differences in major allergen content were found between samples. All
samples were reactive in commercial ELISAs for detection and quantification of peanut protein. IgE-
binding potency differed between samples with a maximum factor of 2, indicating a highly comparable
allergenicity.
Based on our observations, we conclude that peanuts from the main market types consumed
in Western countries are highly comparable in their allergenicity attributes, indicating that safety
considerations with regard to peanut allergy are not dependent on the peanut cultivar in question.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Peanut (Arachis hypogaea L) is a seed crop legume that is widely
used for human food purposes because of its high nutrition value
(Oerise et al., 1974) and sensory attributes. The overall annual
production of peanut (including Runner, Virginia, Spanish, and
Valencia) in the U.S. in 2014 was 2.4 million tons (Anonymous,
USDA NASS report, 2015) harvested from 1.4 million acres. The
primarily grown species of peanut include two subspecies: hypo-
gaea (Virginia market type) and fastigiata, the latter divided into
two varieties fastigiata vulgaris (Spanish market type) and fastigiata
fastigiata (Valencia market type). The Runner market type is a
hybrid of fastigiata and hypogaea subspecies (Krapovicakas, 1969)
and accounts for the majority (78.7%) of the U.S. peanut production.
The Virginia market type accounts for approximately 19.9% of the
U.S. peanut production. The Runner type is used primarily for the
manufacture of peanut butter, and the large-kernelled Virginia type
is marketed mainly as snack peanut and in-the-shell peanut
products. The Spanish and Valencia market types are commercially
less important, representing a combined 1.4% of the overall U.S.
peanut production. The Spanish type, with rounder and smaller
kernels, is used for snack peanuts, peanut butter and confections
while the longer podded Valencia type, containing three to five
kernels in each shell, is marketed mostly in the shell for roasting
and boiling (American Peanut Council website, 2015).
Peanuts are widely known as potent allergens and count
together with tree nuts for the majority of anaphylactic reactions to
food (Sicherer and Sampson, 2007). Approximately 0.6% of adults
and 1e2% of children/infants in the U.S. are affected by peanut al-
lergy (Dyer et al., 2015; Sicherer et al., 2010). Unfortunately there is
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no treatment currently available to cure peanut allergy and there-
fore, peanut-allergic patients must avoid consuming peanut.
Several experimental immunotherapies such as oral immuno-
therapy (Anagnostou et al., 2014; Varshney et al., 2011), sublingual
immunotherapy (Burks et al., 2015; Fleischer et al., 2013), and
epicutaneous immunotherapy (Sampson et al., 2015) show prom-
ising results for desensitizing peanut-allergic patients, although
complete tolerance to peanut using these approaches appears to
occur in only a limited number of patients. A new approach using
modified peanut allergens (Bencharitiwong et al., 2015) for sub-
cutaneous immunotherapy is also currently being investigated
(ClinicalTrials.gov identifier NCT02163018). The active compound
for such therapies is essentially based on peanut proteins that can
redirect the immune system. The dosage of peanut protein given in
these therapies is controlled for the efficacy and safety of treat-
ment, but it is not known if the source of peanut protein plays a role
too.
To help peanut allergic consumers adhere to their peanut
avoidance diets, the food industry has invested significant re-
sources to ensure clear labeling of peanut-containing products and
has also developed allergen control best practices to prevent pea-
nut cross-contact in food products produced on shared equipment
or in shared processing facilities. The validation of the effectiveness
of cleaning protocols can be monitored using immunoassays to
detecting peanut residue on equipment surfaces and quantifying
peanut residue in food samples. Such immunoassays have different
sensitivities for specific peanut allergens (Jayasena et al., 2015), i.e.
some detect mainly Ara h3, and others detect mainly Ara h2 and
Ara h2. Because it is not know if different peanut market types
contain different levels of these peanut allergens., it is not known if
certain peanut market types are under- or overestimated with such
assays.
On occasion, pre-packaged food products have been shown to
contain undeclared peanut residue at varying concentrations
(Remington et al., 2013). Studies to quantify the risk that unde-
clared peanut residue poses to peanut allergic consumers who may
eat such products rely on population threshold distributions
modeled from peanut allergic individuals who have undergone a
low-dose peanut challenge using various market types of peanuts
(Taylor et al., 2010, 2015). It is not known if different peanut market
types have different potencies thereby affecting both individual and
population-based thresholds for peanut.
Some studies have investigated differences in the allergenic
properties of various peanut types. It was shown that the four main
market types (Runner, Virginia, Spanish, and Valencia) had com-
parable contents of the major allergens, Ara h 1 and Ara h 2
(Koppelman et al., 2001). Although the analytical tools used in that
studymay have been adequate in that era, quantitation of themajor
allergens would nowadays require more sophisticated analytical
techniques. Also, since the time of that study other major peanut
allergens have been identified that should also be taken into ac-
count. A more recent study compared different cultivation condi-
tions on the allergen composition of Spanish peanuts (Walczyk
et al., 2013) while Kottapalli et al. (Kottapalli et al., 2008) used 2D
electrophoresis and proteomics to compare the protein profiles of
the four market types commonly grown in the U.S. (Runner, Vir-
ginia, Spanish, and Valencia). The authors conclude that Valencia
and Runner market types do not contain Ara h 3; however, the 2D
gels indicate spots at the approximate position of Ara h 3 that were
not identified. Due to complex post-translational processing of Ara
h 3 (Piersma et al., 2005), it may migrate in 1D and 2D gel elec-
trophoresis conditions at positions deviating from what is ex-
pected, possibly explaining why the authors concluded that Ara h 3
is absent in Valencia and Runner peanuts (Kottapalli et al., 2008).
Another proteomics study made a detailed analysis of the proteins
present in two different peanut types, i.e. Virginia and an Indone-
sian type named Kacang Asin or Bali peanut (Schmidt et al., 2009).
Over 100 protein spots from 2D electrophoresis were identified,
and it was shown that the level of Ara h 1was substantially lower in
the Kacang Asin peanut (Schmidt et al., 2009). Other peanut aller-
gens were present in both peanut types in comparable amounts,
but the analytical techniques used were only semi-quantitative, i.e.
intensity if mass spectrometry signals (Schmidt et al., 2009).
This study quantitatively compares the allergenicity of the four
main peanut market types (Runner, Virginia, Spanish, and Valen-
cia). We have determined the protein content and protein profiles,
and have applied different immunoassays to compare antigenic and
allergenic potency. Furthermore, we have applied a reversed-phase
HPLC method to quantify the allergens Ara h 1, Ara h 2, Ara h 3 and
Ara h 6. This knowledge will serve in the development of well-
characterized peanut immunotherapy materials for peanut al-
lergy, and will also support risk-assessment and food safety pro-
grams for the food industry.
2. Material and methods
2.1. Reference peanut allergens and peanut kernel samples
The purified peanut allergens, Ara h 1, Ara h 2, Ara h 3 and Ara h
6, were obtained from lyophilized stock preparations made as
described earlier (de Jong et al., 1998; Koppelman et al., 2003,
2005). Virginia peanuts were obtained from the North Carolina
State University Department of Crop Science (Raleigh, NC), Runner
and Spanish peanuts from the USDA-ARS National Peanut Research
laboratory (Dawson, GA), and Valencia peanut from the New
Mexico State University Agricultural Science Center (Clovis, NM).
All peanut samples were used raw. Table 1 provides an overview of
the peanut cultivar samples. Peanuts were shelled and initially
stored according to the guidelines for cold storage of peanuts
(American Peanut Council, 2006) for several months. The peanut
kernels were later repackaged and stored at 20 C. The nitrogen
content of the intact peanut kernels was determined by the com-
bustion method using a LECO FP-428 nitrogen analyzer at 950 C
combustion temperature (LECO Corp., St. Joseph, MI). Conversion to
protein was done by multiplying the nitrogen value with 5.46
(Jones, 1931).
2.2. Preparation of extracts
10 to 15 g of peanut kernels was manually ground with a mortar
and pestle until a fine, homogeneous paste was obtained. Three
different extracts were prepared. The first series of extracts was
prepared by mixing 2 g of ground peanut with 20 mL of extraction
buffer (0.01 M Ammonium-bicarbonate, pH 7.9) in a 50 mL Falcon
tube. Tubes were vortexed and placed in a rotator device (10 rpm)
overnight at 2e8 C. Tubes were centrifuged at 4500 rpm
(2830 g) for 45min at 4 C, and an aliquot of the middle layer was
collected and transferred into 15 mL tubes and centrifuged again
(4500 rpm; 2830  g) for 45 min at 4 C. Again, an aliquot of the
middle layer was collected and transferred to several 1.5 mL tubes
and centrifuged at 14,000 rpm (10,000  g) for 20 min at room
temperature (RT). Clarified solutions were collected from the
middle portion of each microcentrifuge tube; these were pooled
per sample, aliquoted in small volumes and stored at 80 C until
further use. Where transportation was required, samples were
shipped frozen. The soluble protein concentration in the pooled
extracts was determined by Bradford analysis (SigmaeAldrich,
USA) using a bovine serum albumin standard (SigmaeAldrich) and
a UV/Vis spectrophotometer (PerkinElmer, USA). This first series of
extracts is referred to as aqueous extracts and was used for protein
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concentration determination, SDS-PAGE analysis, ELISA, and RP-
HPLC analysis. The second series of extracts was made by mixing
20 mg of ground peanut with 0.5 mL of non-reducing Laemmli
buffer (8% glycerol, 4% SDS, and 0.01% bromphenol blue in 0.066 M
Tris HCl, pH 6.8) in the absence of a reducing agent. Suspensions
were mixed and then centrifuged at 1400 rpm (100  g) for
20 min at RT and subsequently at 70 C for 20 min. Supernatants
were collected and stored at 20 C until use. The same procedure
was used to prepare the third series of extracts, except that the
Laemmli buffer contained 1% b-mercapto-ethanol as a reducing
agent. The second and third series of extracts were used for SDS-
PAGE analysis only, and are referred to as SDS extracts.
2.3. SDS-PAGE analysis
SDS-PAGE analysis was performed with 12% Bis-Tris gels (XCell
SureLock Mini-Cell; Invitrogen, USA) according to the instructions
of themanufacturer. Aqueous extracts were diluted to 2mg/mL and
then mixed (1:1 V/V) with 2  concentrated Laemmli buffer, either
in the presence or absence of 2% b-mercapto-ethanol. SDS extracts
were diluted 10-fold in Laemmli buffer, either in the presence or
absence of 1% b-mercapto-ethanol, resulting in a load of 6 mg/lane.
Molecular weight marker was from ThermoFisher Scientific,
product reference Mark 12, catalogue number LC5677, Following
electrophoresis, gels were incubated for 1 h in 12% TCA as a fixation
step, and proteins were subsequently visualized by SimplyBlue
SafeStain (Invitrogen, USA) according to the instructions of the
manufacturer.
2.4. Reverse-phase HPLC
RP-HPLC experiments were performed on an Agilent 1200 sys-
tem operated by ChemStation software. UV detection was per-
formed at 215 nm. Aqueous peanut extracts' were analyzed on an
XBridge Phenyl column (2.1 mm  150 mm, 3.5 mm particle size,
Waters Chromatography). The columnwas protected by an Xbridge
Phenyl guard cartridge (2.1 mm  10 mm, 3.5 mm particle size,
Waters Chromatography). The mobile phase solvent A consisted of
0.1% TFA (V/V) whereas the mobile phase solvent B contained
acetonitrile with 0.085% TFA(V/V) The column was equilibrated
with 90% solvent A and 10% solvent B. The columnwas run at 50 C
with a flow rate of 0.5 mL/min. After loading the sample (10
diluted, 5 mL injected or 150 diluted, 10 mL injected), the column
was eluted with a gradient of increasing percentage of solvent B
using the following increments: 10% solvent B for 5 min, from 10 to
20% solvent B in 5 min, from 20 to 30% solvent B in 20 min, from 30
to 40% solvent B in 50 min. Subsequently, the columnwas stripped
with 80% solvent B and re-equilibrated with 10% solvent B. Quan-
tification of the major peanut allergens Ara h 1, Ara h 2, Ara h 3 and
Ara h 6 in the different peanut extract samples was performed by
using external calibration curves of the purified native Ara h 1, Ara h
2, Ara h 3 and Ara h 6 (25e400 ug/mL, 5 mL injected, based on A280
measurements and the extinction coefficients of the different al-
lergens), respectively. The amounts of the different major allergens
(in percentages) were calculated in relation to the total protein
content of the aqueous peanut extracts. Measurements were per-
formed in duplicate and the percentages were averaged.
2.5. Peanut ELISA by commercial test kits
Two commercial ELISA test kits were used in this study: the
Neogen Veratox® for peanut allergen (Lansing, MI USA) and the
Morinaga Institute of Biological Science, Inc. Peanut ELISA kit
(Japan). Aqueous extracts were tested (in duplicate) in a broad se-
ries of dilutions (ranging from 0.0125 to 0.1 mg/mL prepared in the
extraction buffers provided by the respective kits), essentially
following the instructions of the kit manufacturers. Plates were
read at the wavelength specified by each kit using a microtiter plate
reader (BioTek Instruments Inc. USA).
2.6. IgE-binding by ELISA
A serum pool was composed of sera from 8 U.S. patients with
peanut allergy (patient's characteristics are summarized in Table 2).
Specific IgE was analyzed by ImmunoCap and ImmunoCap ISAC
(ThermoFisher, USA). All individual sera had IgE to Ara h 1, Ara h 2,
Ara h 3, and Ara h 6, and five of these sera had additional IgE to Ara
h 8 as well. A serum pool was constructed bymixing equal volumes
Table 1
Protein and major allergen content of peanut samples.
Sample Total protein Major allergen content










Leco analysis Bradford analysis
(% W/W) (mg/ml)
1 Exp-27-1516 Runner 27.6 21.5 78% 12.1 4.4 77.7 3.8
2 GA06G Runner 25.3 20.7 82% 15.4 5.8 82.5 4.2
3 Tiftguard Runner 26.8 19.9 74% 16.1 6.3 71.4 3.7
4 Flo7 Runner 26.4 21.7 82% 11.7 4.5 78.0 4.4
5 Florunner 4/14 Runner 29.3 17.8 61% 17.8 5.5 75.9 2.5
6 Olin Spanish Spanish 28.9 23.6 82% 15.3 5.7 83.5 4.8
7 Valencia C Valencia 29.7 24.3 82% 14.6 6.5 80.1 4.8
8 Valencia A Valencia 26.3 20.5 78% 17.1 4.5 77.9 4.1
9 H&W 102 Valencia 26.7 17.8 67% 14.1 3.5 69.9 5.2
10 NC9 Virginia 21.6 14.5 67% 20.9 8.0 58.0 9.7
11 NC10C Virginia 25.6 15.6 61% 22.0 7.3 82.7 5.7
12 NC-V11 Virginia 24.7 15.9 64% 22.1 6.6 57.7 6.3
13 NC 12C Virginia 20.7 18.1 87% 16.4 7.2 62.2 7.6
14 Gregory Virginia 24.3 17.7 73% 19.1 6.8 61.9 6.9
15 Perry Virginia 22.2 17.7 79% 14.5 6.1 62.3 8.0
16 Phillips Virginia 21.4 15.8 74% 23.7 8.0 62.8 7.8
17 Brantley Virginia 21.8 18.3 84% 16.9 5.7 65.9 7.8
18 Bailey Virginia 24.7 14.9 60% 21.4 7.8 68.7 6.0
19 Sugg Virginia 25.0 19.8 79% 15.3 7.0 69.9 6.4
20 Champs Virginia 24.0 19.5 81% 15.2 6.6 64.0 5.3
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of individual serum. Peanut-specific and individual peanut
allergen-specific IgE levels in this pool were confirmed (Table 2).
Serum from both an atopic patient with no peanut allergy and a
non-atopic patient were included as negative controls.
IgE-ELISA was performed essentially as described earlier17 with
some modifications. Maxisorp microtiter plates (Nunc Maxisorp
flat bottom immune plates, Rochester, NY) were coated with 100 mL
per well of 5 mg/mL of peanut extract #1 (sample 1 in Table 1)
prepared in coating buffer (15 mM Na2CO3, 35 mM NaHCO3; pH
9.6), and incubated overnight at 4 C. Plates were washed with
0.01 M phosphate buffered saline containing 0.05% (V/V) Tween 20
(PBS-T, pH 7.4) and subsequently blocked with PBS-T containing 1%
BSA. For each peanut cultivar extract (#1 to 20), a series of dilutions
ranging from0 to 2000 mg/mLwas prepared in blocking buffer. Each
of these dilutions was mixed 1:1 with the pooled sera that had
already been pre-diluted 15 fold in blocking buffer and incubated at
37 C for 2 h. The pre-incubated serum þ inhibitor mixtures were
then transferred to the coated ELISA plates and incubated for 2 h at
37 C. The plates were washed with PBS-T and incubated for 1 h at
37 C with 100 mL/well of mouse anti-human IgE conjugated with
HRP diluted 1:15,000 in blocking buffer. Plates were again washed
with PBS-T and 100 mL per well of TMB substrate was added and
incubated in the dark for 15 min. The reaction was then stopped by
adding 100 mL per well of 1N HCl. The absorbance of each well was
measured at 450 nm using a microtiter plate reader (BioTek In-
struments Inc. USA). Assays were performed in triplicate. Concen-
trations of peanut protein required for 50% inhibition (IC50) of IgE-
binding were calculated as described previously (Koppelman et al.,
2001).
3. Results and discussion
3.1. Protein content of peanut kernels and aqueous extracts
The intact peanut kernels contained proteins levels ranging
from 20.7 to 29.7% (relative to total weight) with a mean protein
content for all samples of 25.2 ± 2.7% (Table 1), which is in line with
known average values of protein content in peanut (Oerise et al.,
1974). The differences we see in protein content between the
samples can be explained by both genetic and environmental fac-
tors, in particular the variety cultured and climate and weather
conditions (Cobb and Johnson, 1973). In aqueous extracts with the
protein content determined by Bradford analysis (Table 1), the
levels of soluble peanut protein were somewhat lower than
predicted based on the 25% protein content of intact peanut kernels
(60e81% of predicted). The samples extracted 1:10 (w/v) should
have contained a theoretical concentration of 25 mg/mL if all of the
protein in the kernel was solubilized and subsequently extracted.
Sathe et al. also found that extractable protein for peanut as
determined by the Bradford method was somewhat lower that the
theoretically expected value based on the nitrogen content of
peanut kernels (Sathe et al., 2009). This can be due to incomplete
extraction (Leco analysis measures the nitrogen content in the solid
material of peanut, independent on extractability or solubility of
different proteins), or because the two methods are calibrated by
different means.
3.2. Protein profile
Fig. 1 shows the protein profiles of the aqueous peanut extracts
both under non-reducing and reducing conditions. Purified refer-
ence peanut allergens shown in the first four lanes were used to
assign the bands. Ara h 1, peanut vicilin (7S globulin), migrates at
both non-reducing and reducing conditions at approximately
63 kDa. Ara h 2 and Ara h 6, peanut conglutin (2S albumin), migrate
at approximately 15/17 and 13 kDa, respectively, under non-
reducing conditions and at 17/19 and 15 kDa under reducing con-
ditions due to unfolding of the tight protein core (Apostolovic et al.,
2013). Ara h 3, peanut legumin (11 S), consists of an N-terminal and
C-terminal chain that are held together by disulfide bridges
(Piersma et al., 2005). The N-terminal chain is extensively post-
translationally processed, leading to various molecular weights and
Ara h3, under non-reducing conditions, migrates as various bands.
Upon reduction, the two chains are dissociated resulting in 14, 42/
45 kDa (N-terminal, acidic chain) and 25 kDa (C-terminal, basic
chain) bands (Piersma et al., 2005). Under non-reducing conditions,
Ara h 1 and Ara h 3 co-migrate, while Ara h 2 and Ara h 6 are well
separated from Ara h 3 (basic 25 kDa chain). Under reducing con-
ditions, Ara h 1 and Ara h 3 are well separated, at the costs of lower
resolution of Ara h 2, Ara h 6, and the 25 kDa basic chain of Ara h 3.
With both electrophoretic conditions in place, each individual
allergen can be assigned more reliably. Fig. 1 clearly shows that all
of the peanut extracts contained Ara h 1, Ara h 2, Ara h 3 and Ara h
6. Qualitatively, the intensities of these allergens are similar be-
tween different peanut extracts, although only semi-quantitative
statements can be made based on the SDS-PAGE data. Under
reducing conditions, the N-terminal chain of Ara h 3 appears
differently among various cultivar samples. The majority (16/20) of
Table 2
Patient characteristics and serology.
Subject# Sex/Age (yr) Case historya Other food allergyb Other atopy SPTc IgE (ISU)d IgE (kUa/L)e
Peanut Ara h 1 Ara h 2 Ara h3 Ara h 6 Ara h 8 Ara h 9 Peanut Peanut
1 F/13.9 RA, P, U, AE, W, E, P(H) a yes 9 51.7 64.5 27.1 76 5.15 0 224.38 53
2 M/35 SZ, P(UR), L, R, N, AP, LS, OAS e, s, tn, pe, bn, ln yes 35 60.4 31.3 15.1 64.5 2.05 0 141.38 575
3 F/24 P, L, W, C, N, DY, OAS s, tn, ml, ap, st yes 20 50.2 24 14.5 50.2 2.48 0 378.36 72.5
4 M/19 W, TS, P a, h no 12 96.7 98.5 58.2 124.3 0.67 0 173.27 787
5 F/32 AS, NC, DY s, tn, m, f yes ND 39.6 22.3 3.42 8.43 35.4 0 n.d. 30.1
6 M/35 L, AE, U, AP s, l, tn, c, f no 15 57.7 18.4 5.71 21.3 0 0 n.d. 85.5
7 M/35 LS, U, DY, E, OT unknown unknown ND 33.4 30.2 29.6 15 0 0 n.d. 74.3
8 M/32 DY,U, AE, s, pe, ln, c, cs unknown ND 10.6 9.26 0.83 10.7 0 0 n.d. 15.4
Pool n.a. n.a. n.a. n.a. n.a. 53.4 39.3 15.2 76.5 4 0 251 n.d.
n.a.: Not applicable; n.d. Not determined.
a AE: angioedema; AP: abdominal pain; AS: asthma; C: cough; DY: dypsnea; E: emesis; L: laryngeal edema; LS: lip swelling; N: nausea; NC: nasal congestion; OAS: oral
allergy symptoms; OT: odd taste; P (H), (UR):pruritis (hand), (upper respiratory); R: rhinorrhea; RA: rash; SZ: sneeze; TS: tongue swelling; U: urticaria; W: wheeze.
b a: almond; ap: apple; bn: bean; c: crustacea; cs: cashew; e: egg; f: fish; h: hazelnut; l: legumes; ln: lentil; m: milk; ml: melon; pe: pea; s: soy; st: strawberry; tn: tree nut.
c Skin prick test; diameter of wheal in milimeters.
d Peanut IgE by ISAC (ISU).
e PN ICAP: Specific IgE to peanut (ImmunoCAP value for serum IgE) expressed in kUa/L.
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samples have a triplet at 40e45 kDa. Some samples (no. 12, 14, 16,
and 18) lack the lowest band of this triplet. Furthermore, with some
samples (no. 5,11, and 13) the intensity of this band is lower. For the
samples that lack this band or have this band at low intensity, the
intensity of a band at approximately 30 kDa is higher (indicated in
Fig. 1B for samples 9 and 10 as examples). This band is also present
in purified Ara h 3 and was earlier shown to be a post-
translationally processed part of the N-terminal chain of Ara h 3
(Piersma et al., 2005). There seems to be a correlation between the
lower intensity (or absence) of the lower band of the 42e45 kDa
triplet with the intensity of the 30 kDa band, however not for all
samples. In particular sample 4, inwhich both the lower band of the
42e45 kDa triplet as well as the 30 kDa band can be observed.
Apparently in peanut kernels, Ara h 3 can be found at different
stages of post-translational processing. This phenomenon is not
observed for the C-terminal chain of Ara h 3, or Ara h 1, Ara h 2, and
Ara h 6 (Fig. 1).
An SDS-containing buffer was used to prepare extracts of
ground peanut in order to increase the efficiency of extracting
lipophilic and amphiphilic proteins such as peanut oleosins
(apparent molecular weights between 14 and 17 kDa (Schwager
et al., 2015)). Schwager et al. demonstrated extraction of lipo-
philic and amphiphilic proteins with a similar SDS-containing
buffer (Schwager et al., 2015). The protein profiles of the extracts
obtained with SDS-containing buffer (Fig. 2) show similar proteins
bands to those of the aqueous extracts (Fig. 1). A minor difference
may be the faint band at approximately 150 kDa that can be
observed in the profiles of extracts made with the SDS-containing
buffer. This band is trimeric Ara h1 with different solubility
(Maleki et al., 2000), and appears to be soluble in the presence of
SDS. The trimeric form of Ara h1 can also be observed as minor
band in the protein profile of purified Ara h1, in line with literature
(Maleki et al., 2000). For both extraction conditions we see bands at
the 14e17 kDa molecular weight area. Some of these bands are
from Ara h2, Ara h3, and Ara h6, but some other bands with low
intensity are unassigned and may be oleosins. Having no further
data available, we can only speculate on this. Overall the aqueous
extraction was efficient in extraction of similar proteins from the
ground peanut kernels compared to extraction of peanut protein
with the SDS-containing buffer. The optimized pH (8.2) and the
long duration of extraction may have contributed to this
observation.
3.3. Quantification of major allergens Ara h 1, Ara h 2, Ara h 3, and
Ara h 6 by RP-HPLC
The RP-HPLC method allowed the identification and quantifi-
cation of the major peanut allergens (Ara h 1, Ara h 2, Ara h 3 and
Ara h 6) in extracts from several commercially important peanut
market types. These allergens appear as separate peaks in the
chromatograms of the samples (Fig. 3), and exhibit the same
elution characteristics of the reference proteins Ara h 1, Ara h 2, Ara
Fig. 1. Protein profiles of aqueous extracts of peanut samples. Panel A: Non-reducing conditions. Panel B: Reducing conditions. M: Marker proteins (indicated in the left margin in
kDa); h1: Ara h 1 (1 mg/lane); h2: Ara h 2 (2 mg/lane); h3: Ara h 3 (5 mg/lane); h6: Ara h 6 (1 mg/lane). Numbers 1 to 20 refer to sample numbers as described in Table 1; 6 mg/lane was
loaded.
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h 3 and Ara h 6. Table 1 summarizes the amount of each allergen
present in the extracts and expressed as a percentage of the total
protein in the extracts. These values are abased on comparison of
the surface areas of the relevant peaks with those of known
amounts of reference proteins. Based on our quantitative analysis,
we estimate that Ara h 1 ranges from 11.7 to 23.7%, with a mean
(±SD) of 17.1 (±3.4) %. Ara h 2 ranges from 3.5 to 8.0% with a mean
(±SD) of 6.2 (±1.3) %. These values are in line with earlier work
Fig. 2. Protein profiles of SDS extracts of peanut samples. Panel A: Non-reducing conditions. Panel B: Reducing conditions. M: Marker proteins (indicated in the left margin in kDa);
h1: Ara h 1 (1 mg/lane); h2: Ara h 2 (2 mg/lane); h3: Ara h 3 (5 mg/lane); h6: Ara h 6 (1 mg/lane). Numbers 1 to 20 refer to sample numbers as described in Table 1; a theoretical
amount (based on the assumption that peanut contains 25% protein) of 8 mg/lane was loaded.
Fig. 3. RP-HPLC chromatograms of an aqueous peanut extract and the purified peanut major allergens. X-axis: Elution time in minutes; Y-axis: Absorbance at 215 nm (mAU). Upper
panel: Aqueous peanut extract of sample 1. Lower panel: mix of equal amounts (200 mg/mL, 5 mL injected) of purified peanut allergens Ara h 1, Ara h 2, Ara h 3, and Ara h 6 (indicated
in text boxes).
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showing that Ara h 1 and Ara h 2 in similar peanut market types
ranged from 12 to 16% (Ara h 1) and from 5.9 to 9.3%, (Ara h 2)
(Koppelman et al., 2001). Ara h 3 is clearly the most abundant
protein in all samples, with an estimated range from 57.7 to 83.5%
with a mean (±SD) of 70.6 (±8.6) %. No previously published data
quantifying the Ara h 3 content of peanuts is available; however,
the large quantity of Ara h 3 in peanut is nevertheless expected
since the bands of Ara h 3 dominate the peanut protein profile as
shown in this study (Figs. 1 and 2) and many other publications
(Hefle et al., 1995; Koppelman et al., 2003; Fu and Maks, 2013;
Zhuang and Dreskin, 2013). There are also no data on the amount
of Ara h 6 in peanut. Based on our analysis, we estimate that Ara h 6
content ranges from 2.5 to 9.7% with a mean (±SD) of 5.8 (±1.8) %.
As expected based on the protein profiles (Fig. 1), all four allergens
were present in all tested samples. The ranges of major allergen
content are not substantially different between different market
types, or between varieties within a single cultivar (Runner and
Virginia). The minor differences we see may be explained by the
genetic background of the peanut and climate and weather con-
ditions. These factors are known to influence the protein content of
peanut kernels and may as well affect the expression of individual
proteins. However, at this stage we have no data to support this
hypothesis.
A clinical study applying skin-prick tests demonstrated that
peanut allergens Ara h 2 and Ara h 6 are 100- to 1000-fold more
potent than Ara h 1 and Ara h 3 (Peeters et al., 2007), and it is
therefore important to closely evaluate Ara h 2 and Ara h 6 spe-
cifically. Even though these allergens are less abundant (around 6%
each, together approximately 12% of the total protein in peanut)
compared to Ara h 1 and Ara h 3 (about 17% and 71%, respectively;
Table 1), they may dominate the allergenic potential of peanut
protein. The observation that levels of both Ara h 2 and Ara h 6
differ a maximum of about 2- to 3-fold between samples suggests a
minimal impact on the overall difference in allergenicity among
peanut market types, cultivars or varieties.
3.4. Reactivity in commercial kits for peanut residue detection and
quantification
When the peanut extracts were evaluated by two commercially
available peanut ELISA kits (Neogen Veratox® for Peanut Allergen
kit and the Morinaga Institute of Biological Science, Inc. Peanut
ELISA kit) at a normalized protein concentration of 1 mg/mL, the
Neogen kit overestimated the peanut protein content (about 4-fold
compared to the expected value) and the Morinaga kit under-
estimated the content (mean of 60% of the expected value). A
similar observation has been reported by Jayasena et al. with these
two kits with the NIST (National Institute of Standards and Tech-
nology, Gaithersburg, MD) standard reference material 2387 pea-
nut butter and is most likely due to the calibration of the kits for
which the kit manufacturers supply their own independent stan-
dard in absence of international standard materials (Jayasena et al.,
2015). The ranges of reactivity of the samples are from 2.8 to
4.5 mg/mL (mean ± SD ¼ 4.0 ± 0.5) for the Neogen kit, and 0.44 to
0.92 (mean ± SD ¼ 0.6 ± 0.1) mg/ml for the Morinaga kit (Table 3).
Jayasena et al. (2015) showed that these two kits have distinctly
different specificities for the major allergens. The Neogen kit de-
tects predominantly Ara h 3with about a 30-fold lower reactivity to
Ara h 1, while Ara h 2 and Ara h 6 are minimally recognized. The
Morinaga kit recognizes Ara h 2 and Ara h 6, but had very low
recognition of Ara h 1 and Ara h 3 (both about 1000-fold less
reactive; Jayasena et al., 2015). A comparison was made between
the peanut protein content of the samples assayed with the Mor-
inaga kit and the sum of Ara h 2 and Ara h 6 as determined by RP-
HPLC. Although all samples are relatively close to each other, there
is a positive correlation between the two parameters (R2 ¼ 0.895).
An inverse correlation was found between the reactivity in the
Morinaga kit and the Ara h 3 content as determined by RP-HPLC
(R2 ¼ 0.63). Reactivity in the Neogen kit was not related to con-
tent of any of the peanut allergens specifically, possibly because this
ELISA recognizes two different types of peanut allergens (Ara h 3
and to a lesser extent Ara h 1).
3.5. Reactivity in IgE-binding assay
To compare the IgE-binding potency of the different peanut
samples, the aqueous extracts were tested in a competitive inhi-
bition IgE-ELISA using a pool of sera from peanut-allergic patients
as a source of IgE. Because such ELISAs have no standard or refer-
encematerial, sample #1 was used as the basis to compare all other
samples. IgE-binding to peanut protein from sample #1 was
inhibited with sample #1 itself (positive control) and all other
samples, and the concentration needed to inhibit 50% of this signal
was calculated (IC50). Table 3 shows the IC50 values which ranged
from 0.20 to 0.41 mg/mL. Attempts to make allergen extracts or
allergens hypo-allergenic, for example by chemical modification or
biotechnological modification, aim to reduce the IgE-binding at
least 100-fold, preferably more (Apostolovic et al., 2013; Ibarrola
et al., 2004; Swoboda et al., 2007; van Bilsen et al., 2013;
Versteeg et al., 2011). The narrow range of IC50 values reported
here (only a 2-fold difference) indicates that the peanut samples
have a highly comparable IgE-binding potency. This small differ-
ence in IgE inhibition between the most and least potent sample is
in line with the weak positive correlation between IgE-binding
potency and the content of Ara h 1, Ara h 2 and Ara h 6, and a
(weak) inverse relation between IgE-binding potency and content
of Ara h 3 (R2 ¼ 0.42, 0.34, 0.21, and 0.11 for Ara h 1, Ara h 2, Ara h 6
and Ara h 3, respectively). Correlation coefficients are most likely
low due to the narrow range inwhich the parameters vary (2- to 3-
fold). Together this may suggest that Ara h 3 is not as relevant of an
IgE-binding protein, as Ara h 1, Ara h 2 and Ara h 6, the peanut
allergens of primary concern. This is in line with the current un-
derstanding of the relevance of individual peanut allergens (Chen
et al., 2011; Ballmer-Weber et al., 2015).
3.6. Consequences for allergenicity
We have compared the allergenicity attributes of 20 peanut
varieties, i.e., protein content and profile, major allergen content,
IgG- and IgE-binding potencies. These attributes are highly com-
parable for all samples. The peanut varieties included in this study
are most relevant for human consumption, both in the U.S. and in
other Western countries. Currently in U.S. peanut production,
GA06G (sample no. 2) is the dominant Runner type peanut pro-
duced, whereas Bailey (sample no. 18) is the most commonly pro-
duced Virginia type. Together, Runner and Virginia peanuts make
over 98% of the U.S. productionwith Runner at 78.7% and Virginia at
19.9%. Some exotic, naturally occurring, peanut varieties that have
clearly different allergenicity attributes have been described in
literature (Krause et al., 2010; Ramos et al., 2009; Schmidt et al.,
2009), but these peanut types are not commonly consumed in
Western countries. Using genetic modification, attempts were
made to develop new varieties of peanut that are low in certain
allergens (Chandran et al., 2015; Chu et al., 2008; Knoll et al., 2011;
Riascos et al., 2010). None of these peanuts are commercially
available or used by the food industry in the U.S. or other Western
countries.
While we have compared important parameters that are pre-
requisites for allergenicity, we have not compared allergenicity
in vivo. This would require clinical investigations, studies in
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validated animal models, or in cell-based ex-vivo methods, all of
which are beyond the scope of the current study. Nevertheless, a
clinical study carried out by Peeters et al. has shown that Ara h 2
and Ara h 6 are the most potent peanut allergens (Peeters et al.,
2007), and our observation that the levels of these particular al-
lergens do not differ substantially between the peanut types sug-
gests that the in vivo allergenicity of the peanut types will also be
comparable.
Taken together, we believe it is fair to say that there are no
important differences in allergenicity attributes between peanuts
types commonly consumed in Western countries. This has impli-
cations for several disciplines in food science and food allergy
research. First, because the protein content and extractable protein
is highly comparable for all samples, no major differences are ex-
pected for the analysis of samples from food products based on
different peanuts which is an important finding for the food in-
dustry that must design appropriate allergen control plans to
manage peanut cross-contact in shared facilities. This is illustrated
by the results of the two commercial ELISA's for the detection of
peanut. Such assays will provide results independent of the back-
ground of the peanut.
Second, this information will allow the food industry and reg-
ulators to make sound risk assessment and risk management de-
cisions without the need to determine which peanut variety or
varieties are used in a finished food product. Many have assumed
that the allergenic characteristics (content of the major allergens
and potency) of the common peanut market types, cultivars and
varieties used in food products do not different significantly;
however, there was no published data to systematically document
this until now.
Third, several initiatives are ongoing aiming to develop immu-
notherapy for peanut allergy. Such therapy is based on peanut
protein that is administered to patients via different routes. Not all
studies published so far have disclosed the market type of peanuts
that are used, but all have used U.S. peanuts obtained from com-
mercial sources. More importantly, the clinical benefit of these
studies is evaluated by oral food challenges using defined amounts
of peanut protein. Knowing that the different peanut types are very
similar in allergenicity attributes allows comparing food challenge
results from different studies and this facilitates the evaluation of
clinical benefits of the various peanut-immunotherapy studies.
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